Fulgent Genetic (NASDAQ:FLGT) CEO Ming Hsieh bought 7,259 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The shares were purchased at an average cost of $3.28 per share, with a total value of $23,809.52. Following the purchase, the chief executive officer now directly owns 6,540,849 shares of the company’s stock, valued at $21,453,984.72. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Ming Hsieh also recently made the following trade(s):

  • On Thursday, November 16th, Ming Hsieh bought 2,205 shares of Fulgent Genetic stock. The shares were purchased at an average cost of $3.23 per share, with a total value of $7,122.15.
  • On Tuesday, November 14th, Ming Hsieh bought 10,504 shares of Fulgent Genetic stock. The shares were purchased at an average cost of $3.30 per share, with a total value of $34,663.20.
  • On Thursday, November 9th, Ming Hsieh bought 11,520 shares of Fulgent Genetic stock. The shares were purchased at an average cost of $3.47 per share, with a total value of $39,974.40.

Shares of Fulgent Genetic (NASDAQ:FLGT) traded up $0.15 during mid-day trading on Thursday, reaching $3.16. The company had a trading volume of 545,800 shares, compared to its average volume of 46,347. Fulgent Genetic has a fifty-two week low of $2.72 and a fifty-two week high of $13.90. The company has a market capitalization of $53.65 and a PE ratio of 150.50.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/ming-hsieh-buys-7259-shares-of-fulgent-genetic-flgt-stock/1722444.html.

A number of hedge funds have recently made changes to their positions in FLGT. Granahan Investment Management Inc. MA boosted its stake in Fulgent Genetic by 145.5% during the third quarter. Granahan Investment Management Inc. MA now owns 238,232 shares of the company’s stock valued at $1,141,000 after buying an additional 141,182 shares in the last quarter. William Blair Investment Management LLC boosted its position in shares of Fulgent Genetic by 10.4% in the 2nd quarter. William Blair Investment Management LLC now owns 640,219 shares of the company’s stock valued at $4,091,000 after purchasing an additional 60,508 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Fulgent Genetic in the 1st quarter valued at $122,000. Finally, Wells Fargo & Company MN boosted its position in shares of Fulgent Genetic by 2,046.0% in the 1st quarter. Wells Fargo & Company MN now owns 10,730 shares of the company’s stock valued at $118,000 after purchasing an additional 10,230 shares during the period. 16.55% of the stock is owned by institutional investors and hedge funds.

Several brokerages recently weighed in on FLGT. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Fulgent Genetic in a research note on Tuesday, October 24th. Zacks Investment Research raised Fulgent Genetic from a “sell” rating to a “hold” rating in a research note on Wednesday, August 30th. Raymond James Financial, Inc. cut Fulgent Genetic from an “outperform” rating to a “mkt perform” rating in a research note on Tuesday, November 7th. ValuEngine raised Fulgent Genetic from a “sell” rating to a “hold” rating in a research note on Monday, October 2nd. Finally, Credit Suisse Group decreased their target price on Fulgent Genetic from $11.00 to $10.00 and set an “outperform” rating for the company in a research note on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $7.25.

About Fulgent Genetic

Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.

Insider Buying and Selling by Quarter for Fulgent Genetic (NASDAQ:FLGT)

Receive News & Ratings for Fulgent Genetic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetic and related companies with Analyst Ratings Network's FREE daily email newsletter.